Wednesday, May 9, 2012

Ono Pharmaceuticals report reports earnings for full year ending March 31, 2012

Ono Pharmaceuticals posted sales of Yen 145b, which was up 7% on a year over year basis, while Net income of Yen 24b was flat on a year over year basis. For the full year ending March 2013, Ono is expecting sales of Yen 146b, which implies more or less flat sales, while Net Income per share is expected to decline 6 percent. As far as sales of Major Products are concerned, Galactiv  (type 2 diabetes) grew 168%. On the R&D side, Development of ONO-5334 for the treatment of osteoporosis was discontinued comprehensively taking into consideration competitiveness as well as marketing conditions in osteoporosis area